Background/Aim: Barrett’s oesophagus can be expected to be more resistant to the effects of acidic refluxate, and, hence, it can be postulated that patients with Barrett’s oesophagus experience less reflux complaints. A cross-sectional study in consecutive patients presenting with Barrett’s oesophagus and reflux oesophagitis was done in order to test this hypothesis. Methods: Patients received a standardized questionnaire, and overall and specific symptom scores were assessed on a five-point Likert scale. Results: Reflux oesophagitis was diagnosed in 128 patients and Barrett’s oesophagus in 42. Patients with reflux oesophagitis had statistically significantly higher symptom scores than patients with Barrett’s oesophagus (mean ± SD): 9.1 ± 6.3 vs. 6.2 ± 5.4 (p = 0.01). The scores for heartburn and acid regurgitation were significantly higher in reflux oesophagitis, while there was a trend for epigastric pain, retrosternal pain, and vomitus. The symptom scores of patients with Barrett’s oesophagus older than 60 years were not different from patients with reflux oesophagitis older than 60 years: 5.2 ± 4.8 vs. 7.4 ± 6.4. However, the symptom scores of patients younger than 60 years were significantly higher in those with reflux oesophagitis: 10.2 ± 5.7 vs. 7.2 ± 5.7 (p = 0.04). Odynophagia, heartburn, and acid regurgitation scored significantly higher in patients with reflux oesophagitis younger than 60 years as compared with Barrett patients younger than 60 years. Conclusions: Patients with Barrett’s oesophagus indeed suffer less from reflux complaints. However, this is only true for those younger than 60 years.

Journal Section:
Original Paper: Esophageal Disorders
Keywords:
Reflux complaints, Barrett’s oesophagus, Gastro-oesophageal reflux disease
1.
DeMeester TR, Peters JH, Brenner CG, Arandrosoma P: Biology of gastroesophageal reflux disease: Pathophysiology relating to medical and surgical treatment. Annu Rev Med 1999;50:469–506.
[PubMed]
https://doi.org/10.1146/annurev.med.50.1.469
2.
Nandurkar S, Talley NJ: Epidemiology and natural history of reflux disease. Baillières Best Pract Res Clin Gastroenterol 2000;14:743–757.
[PubMed]
https://doi.org/10.1053/bega.2000.0122
3.
Jenkins TD, Friedman LS: Adenocarcinoma of the esophagogastric junction. Dig Dis 1999;17:153–162.
[PubMed]
https://doi.org/10.1159/000016920
4.
Savary M, Miller G: The Oesophagus. Solothurn, Gassman, 1978, pp 135–142.
5.
Loffeld RJLF, Stobberingh E, Arends JW: A review of diagnostic techniques for diagnosing Helicobacter infection. Dig Dis 1993;11:173–180.
[PubMed]
6.
Werdmuller BFM, van der Putten ABMM, Veenendaal RA, Lamers CB, Loffeld RJLF: Can screening for IgG antibodies against Helicobacter pylori be used in clinical practice? Omit endoscopy in seropositive or seronegative patients? Dig Dis Sci 1998;43:2296–2300.
[PubMed]
7.
Werdmuller BFM, van der Putten ABMM, Loffeld RJLF: The presentation of reflux oesophagitis, hiatal hernia, Barrett’s oesophagus, and ‘reflux-like’ dyspepsia: A prospective clinical and endoscopic study. Dis Esophagus 1996;9:285–289.
8.
Werdmuller BFM, van der Putten ABMM, Loffeld RJLF: Symptom clusters cannot be used in distinguishing Helicobacter pylori positive or negative patients with functional dyspepsia. Neth J Med 1998;53:164–167.
[PubMed]
9.
Vaezi ME, Richter JE: Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 1996;111:1192–1199.
[PubMed]
10.
Fass R, Pulliam G, Johnson C, Garewal HS, Sampliner RE: Symptom severity and oesophageal chemosensitivity to acid in older and young patients with gastro-oesophageal reflux. Age Ageing 2000;29:125–130.
[PubMed]
11.
Grade A, Pulliam G, Johnson C, Garewal HS, Sampliner RE, Fass R: Reduced chemoreceptor sensitivity in patients with Barrett’s esophagus may be related to age and not to the presence of Barrett’s epithelium. Am J Gastroenterol 1997;92:2040–2043.
[PubMed]
12.
Triadafiloupolos G, Sharma R: Features of symptomatic gastroesophageal reflux disease in elderly patients. Am J Gastroenterol 1997;92:2007–2011.
[PubMed]
© 2001 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2001
You do not currently have access to this content.